Lexaria Announces DehydraTECH-CBD Versus Prescription CBD Program In Treating Seizures
- Lexaria Bioscience Corp (NASDAQ: LEXX) has commenced a new study to compare the effectiveness of Epidiolex to DehydraTECH-cannabidiol (CBD) for reducing seizure activity.
- Related Link: Lexaria Bioscience's Formulated Cannabidiol Lowers Blood Pressure In Hypertension Patients.
- Epidiolex, developed by GW Pharmaceuticals plc, is the first and only FDA-approved CBD medication for seizures associated with two rare and severe forms of pediatric epilepsy.
- The study is designed to investigate if DehydraTECH-CBD has similar or superior levels of efficacy in treating seizures as Epidiolex.
- GW Pharmaceuticals is now sold by Jazz Pharmaceuticals Plc (NASDAQ: JAZZ).
- Animal study EPIL-A21-1 has entered early-stage preparatory work, and results are expected by Q3 2022.
- Also Read: GW Pharmaceuticals' Cannabidiol For Seizures Wins UK Approval.
- Price Action: LEXX shares are up 1.32% at $6.27 during the market session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs cannabidiolBiotech News Health Care Movers Trading Ideas General
